Despite a significant decrease in LV mass index severity over time, the overall prevalence of LVH remains high in pediatric kidney transplant recipients, indicating continuous cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Persistent LVH prevalence signals ongoing CV risk; leaves open whether targeted interventions can further regress hypertrophy in pediatric transplant recipients.
Cross-sectional studies indicate that LVH, known cardiovascular risk factor, is frequent in pediatric patients post-kidney transplant. We performed a retrospective longitudinal analysis of echocardiographic data collected in children and adolescents who received kidney transplant from 1998 to 2003. The first echo was performed at a median time post-transplant of 14 months in 47 children; a second echo (echo 2) was carried out at a median time of 33 months in 31 and a third echo (echo 3) was performed at a median time of 49 months in 14 children. LVH was defined as LV mass index >/=95th percentile for children. LVH was present in echo 1 in 25 (54%) subjects. Systolic blood pressure (p = 0.02) and BMI (p = 0.02) independently predicted the LVH seen in echo1 in multivariate logistic regression. In 14 subjects with three consecutive echocardiograms LVM index significantly decreased from echo 1 to echo 2 and from echo 1 to echo3 (p < 0.05), but no significant changes were observed between echo 2 and echo 3. The overall prevalence of LVH remained unchanged but its severity significantly decreased during the follow-up. The results of the study suggest that despite regression of LVM index overtime-pediatric patients post-kidney transplant are at continuous risk for developing cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Bullington et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: